Home » Topics » BioWorld Science

BioWorld Science
RSS

Aradigm tests inhalation form of morphine in volunteers

Nov. 14, 1997

Biomira: Q3 1997 highlights

Nov. 14, 1997

nNOS inhibitor from Astra effective in animal models of stroke, ALS

Nov. 14, 1997

Roche in-licenses promising antiparkinsonian agent

Nov. 14, 1997

Xoma develops potential new diagnostic tool for severe infections and sepsis

Nov. 14, 1997

New vascular gene therapy company established with initial focus on VEGF-2

Nov. 14, 1997

ImClone receives SBIR grant for angiogenesis research

Nov. 14, 1997

T-614, a new NSAID that appears to act as a lysosomal protease inhibitor

Nov. 14, 1997

KE-298 suppresses MMP production in RA synoviocytes

Nov. 14, 1997

First interim phase III safety results reported for OxSODrol

Nov. 14, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...